<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lipocortin-1 (annexin-1) is an endogenous <z:chebi fb="7" ids="16670">peptide</z:chebi> with antiinflammatory properties </plain></SENT>
<SENT sid="1" pm="."><plain>We have previously demonstrated lipocortin immunoreactivity in certain glial cells and neurons in the rat brain (Strijbos, P.J.L.M., F.J.H </plain></SENT>
<SENT sid="2" pm="."><plain>Tilders, F </plain></SENT>
<SENT sid="3" pm="."><plain>Carey, R </plain></SENT>
<SENT sid="4" pm="."><plain>Forder, and N.J </plain></SENT>
<SENT sid="5" pm="."><plain>Rothwell </plain></SENT>
<SENT sid="6" pm="."><plain>1990 </plain></SENT>
<SENT sid="7" pm="."><plain>Brain Res </plain></SENT>
<SENT sid="8" pm="."><plain>In press.), and have shown that an <z:chebi fb="0" ids="29318,29339">NH2</z:chebi>-terminal fragment (1-188) of lipocortin-1 inhibits the central and peripheral actions of cytokines on <z:hpo ids='HP_0001945'>fever</z:hpo> and thermogenesis in the rat in vivo (Carey, F., R </plain></SENT>
<SENT sid="9" pm="."><plain>Forder, M.D </plain></SENT>
<SENT sid="10" pm="."><plain>Edge, A.R </plain></SENT>
<SENT sid="11" pm="."><plain>Greene, M.A </plain></SENT>
<SENT sid="12" pm="."><plain>Horan, P.J.L.M </plain></SENT>
<SENT sid="13" pm="."><plain>Strijbos, and N.J </plain></SENT>
<SENT sid="14" pm="."><plain>Rothwell </plain></SENT>
<SENT sid="15" pm="."><plain>1990 </plain></SENT>
<SENT sid="16" pm="."><plain>Am </plain></SENT>
<SENT sid="17" pm="."><plain>J </plain></SENT>
<SENT sid="18" pm="."><plain>Physiol </plain></SENT>
<SENT sid="19" pm="."><plain>259:R266; and Strijbos, P.J.L.M., J.L </plain></SENT>
<SENT sid="20" pm="."><plain>Browning, M </plain></SENT>
<SENT sid="21" pm="."><plain>Ward, R </plain></SENT>
<SENT sid="22" pm="."><plain>Forder, F </plain></SENT>
<SENT sid="23" pm="."><plain>Carey, M.A </plain></SENT>
<SENT sid="24" pm="."><plain>Horan, and N.J </plain></SENT>
<SENT sid="25" pm="."><plain>Rothwell </plain></SENT>
<SENT sid="26" pm="."><plain>1991 </plain></SENT>
<SENT sid="27" pm="."><plain>Br </plain></SENT>
<SENT sid="28" pm="."><plain>J </plain></SENT>
<SENT sid="29" pm="."><plain>Pharmacol </plain></SENT>
<SENT sid="30" pm="."><plain>In press.) </plain></SENT>
<SENT sid="31" pm="."><plain>We now report that intracerebroventricular administration of lipocortin-1 fragment causes marked inhibition of <z:mpath ids='MPATH_124'>infarct</z:mpath> size (60%) and <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> (46%) measured 2 h after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> (middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>) in the rat in vivo </plain></SENT>
<SENT sid="32" pm="."><plain>The lipocortin-1 fragment was effective when administered 10 min after induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="33" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> caused increased expression of lipocortin-1 around the area of infarction as demonstrated by immunocytochemistry </plain></SENT>
<SENT sid="34" pm="."><plain>Intracerebroventricular injection of neutralizing antilipocortin-1 fragment antiserum increased the size of <z:mpath ids='MPATH_124'>infarct</z:mpath> (53%) and the development of <z:hpo ids='HP_0000969'>edema</z:hpo> (29%) </plain></SENT>
<SENT sid="35" pm="."><plain>These findings indicate that lipocortin-1 is an endogenous inhibitor of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> with considerable therapeutic potential </plain></SENT>
</text></document>